Literature DB >> 2118219

Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity.

K Tanaka1, S Inoue, K Numata, H Okazaki, S Nakamura, Y Takamura.   

Abstract

To determine whether impaired growth hormone (GH) secretion in obese subjects is a consequence of obesity or a pre-existing pituitary-hypothalamic disorder, we measured (1) plasma GH response to growth hormone-releasing hormone (GRH; 1 microgram/kg body weight [BW]), arginine (0.5 g/kg BW), and L-dopa (500 mg); and (2) plasma glucose, insulin, and free fatty acids (FFA) in obese subjects before and after weight reduction due to very-low-calorie diet therapy using Optifast (240 kcal/d for 8 to 12 weeks). Body weight and body mass index (BMI) values before and after weight reduction were 87.2 +/- 4.1 kg and 34.5 +/- 0.9 kg/m2, and 67.8 +/- 2.7 kg and 27.0 +/- 0.4 kg/m2, respectively. GH response to GRH, arginine, and L-dopa in obese subjects was markedly impaired before weight reduction, whereas significantly increased responses were noted after weight reduction (P less than .01). Impaired integrated GH response to GRH, arginine, and L-dopa in obese subjects was significantly restored after weight reduction (P less than .01). Plasma glucose levels did not change, while plasma insulin and FFA levels decreased significantly after weight reduction (P less than .01, P less than .05). There was no significant correlation between integrated GH response to these three stimuli and plasma levels of glucose, insulin, and FFA, respectively. The reversibility of GH response to all three stimuli after weight reduction suggests that impaired GH secretion is a consequence of obesity rather than a pre-existing pituitary-hypothalamic disorder.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118219     DOI: 10.1016/0026-0495(90)90296-o

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.

Authors:  M Maccario; S Grottoli; M Procopio; S E Oleandri; A Barberis; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

Review 2.  Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings.

Authors:  Laurie Wideman; Judy Y Weltman; Mark L Hartman; Johannes D Veldhuis; Arthur Weltman
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

3.  Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index.

Authors:  Ferdinand Roelfsema; Johannes D Veldhuis
Journal:  Neuroendocrinology       Date:  2015-07-28       Impact factor: 4.914

4.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

5.  The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women.

Authors:  Leanne M Redman; Johannes D Veldhuis; Jennifer Rood; Steven R Smith; Donald Williamson; Eric Ravussin
Journal:  Aging Cell       Date:  2009-10-30       Impact factor: 9.304

6.  Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency.

Authors:  C Di Somma; R Pivonello; G Pizza; A De Rosa; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2009-09-30       Impact factor: 4.256

Review 7.  Growth Hormone Stimulation Testing: To Test or Not to Test? That Is One of the Questions.

Authors:  Mabel Yau; Robert Rapaport
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

8.  Plasticity of heart rate signalling and complexity with exercise training in obese individuals with and without type 2 diabetes.

Authors:  J A Kanaley; S Goulopoulou; R M Franklin; T Baynard; M E Holmstrup; R Carhart; R S Weinstock; B Fernhall
Journal:  Int J Obes (Lond)       Date:  2009-08-04       Impact factor: 5.095

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.